There are a variety of pathophysiologic conditions that are known to induce skeletal muscle atrophy. However, muscle wasting can occur through multiple distinct signaling pathways with differential sensitivity between selective skeletal muscle fiber subtypes. This review summarizes some of the underlying molecular mechanisms responsible for fiber-specific muscle mass regulation.
INTRODUCTION
In mammals, skeletal muscle accounts for more than 40% of the mass of a given individual and provides critical functions in metabolism, energy expenditure, physical strength, and locomotor activity. Skeletal muscle is composed of distinct muscle fiber subtypes defined by myosin heavy chain (MyHC) isoforms and metabolic activity. Skeletal muscle fibers are characterized as one type of slow-twitch fiber (type I) and three types of fasttwitch fibers (type IIa, type IIx/d, and type IIb), of which type I and type IIa fibers are oxidative, whereas type IIx and type IIb fibers are primarily glycolytic, although the fiber type specification varies between species (for review see [1 && ]). Muscle mass is dependent upon the relative balance of fiber biosynthesis versus fiber degradation. Muscle biosynthesis occurs at the level of satellite cell myogenesis, fusion with existing fibers, and increased fiber macromolecular synthesis. Decreased muscle mass or atrophy typically results from perturbation of protein degradation induced by a variety of pathophysiologic states such as disuse, unloading, denervation, aging, sepsis, cachexia, glucocorticoid treatment, hereditary muscular disorders, diabetes, kidney, and heart failure. Due to distinct physiological character and metabolic activity (Table 1) , skeletal muscle fiber subtypes are differentially sensitive to specific pathophysiologic atrophy signals. For example, red, oxidative PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-g COACTIVATOR-1
Peroxisome proliferator-activated receptor-g coactivator-1 (PGC1a) is a well described factor required for mitochondrial biogenesis, oxidative metabolism, and slow-twitch fiber formation [6 && ,9 & ,10 & ]. PGC1a regulates oxidative type I fiber formation synergistically with calcineurin/nuclear factor of activated T cells (NFAT) pathway, the latter serving as an essential pathway in the maintenance of the slow-twitch fiber oxidative fiber phenotype [11, 12] .
Several lines of evidence support a role for PGC1a as a positive effector of oxidative skeletal muscle fiber development [6 && ,13]. PGC1a also plays an important role in the control of various signaling pathways involved in skeletal muscle wasting [6 && ]. Overexpression of PGC1a by the muscle creatine kinase (MCK) promoter in transgenic mice had no significant effect on muscle mass at young age but prevented muscle mass wasting in aged mice by inhibiting protein degradation [14] . However, in contrast, other studies of muscle-specific PGC1a overexpression observed muscle atrophy starting at 25 weeks of age [15] . In this model, PGC1a overexpression was equally driven in both slow and fast-twitch muscle depots by the human skeletal actin (HSA) promoter. These transgenic mice have darker-colored muscle fibers, reduced body weight, increased energy expenditure, and muscle atrophy more pronounced in type IIb fibers. Although the basis for these different effects on muscle mass and function remain unknown, one likely explanation is the relative expression levels of PGC1a in these mouse models. The MCK-PGC1a drives PGC1a protein levels similar to endogenous physiological levels present in type I fibers. In contrast, the HSA-PGC1a transgenic mice display more than 10-fold greater levels of PGC1a protein expression. High levels of PGC1a may have negative consequences on macroautophagy due to suppression of FoxO3, since FoxO3 appears to primarily function in muscle degeneration through macroautophagy. In a genetic macroautophagy-deficient model, skeletal muscle atrophy was primarily restricted to type IIb fibers [16 & ]. Thus, it appears that a physiological level of
KEY POINTS
Skeletal muscle type I fiber-specific atrophy and slow-tofast fiber transition can be induced by denervation and immobilization.
Skeletal muscle fiber II specific atrophy is typically induced under cachexia, sepsis, diabetes, and chronic heart failure.
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1a) protects slow, oxidative fibers from atrophy.
Forkhead box O (FoxO) family, transforming growth factor beta (TGFb) family, autophagy inhibition, and nuclear factor kappaB (NF-kB) affect fast, glycolytic fibers more than slow, oxidative fibers. 
FORKHEAD BOX O FAMILY
Forkhead box O (FoxO) transcription factors mediate nutrient and metabolic homeostasis by executing the signals from AKT (also known as protein kinase B, PKB), AMP-activated protein kinase, c-Jun N-terminal kinase, p38, and p300 [7
&&
]. FoxO1 and FoxO3 activity is dependent on nuclear localization and they negatively regulate skeletal muscle mass regulation through ubiquitin/proteasome and autophagy/lysosome systems [7 && ,18]. Their expression is up-regulated under pathophysiologic catabolic conditions, such as denervation/immobilization, fasting, sepsis, and cancer cachexia, whereas inhibited by resistance training [19,20,21 & ]. FoxO1-related muscle atrophy primarily affects fast-twitch fibers. The type II fiber preference of FoxO1 may come from its regulation of muscle RING-finger protein-1 (MuRF1) [21 & ], since MuRF1 is enriched and primarily induced after denervation in type II fibers, and muscle atrophy is reduced in MuRF1 knockout mice [22] . However, there are contradictory opinions about fiber type-specific control of FoxO1 [23, 24] . Endurance training decreases FoxO1 transcriptional activity with a fast-to-slow twitch fiber transition that correspondingly leads to more oxidative genes expression, such as TnI slow and myoglobin [23] . Muscle-specific FoxO1 transgenic mice have more dramatic muscle atrophy in type I fibers than in type II fibers [25] . This may be due to enhanced type I muscle structural protein degradation through FoxO1-mediated lysosomal degradation mediated by cathepsin L [25] and inhibition of calcineurin/NFAT pathway [23] . Further studies are required to clarify the fiber specificity of FoxO1-induced atrophy.
FoxO3 participates in protein degradation, primarily in a macroautophagy-lysosomal pathway [26 & ]. So far, few reports focus on fiber-specific regulation of FoxO3, but FoxO3 may regulate glycolytic fiber atrophy more than oxidative fibers, since PGC1a can suppress FoxO3-induced atrogin expression and PGC1a is much more abundant in oxidative fibers [14] . The apparent role of PGC1a at high expression levels that inhibits FoxO and induces skeletal muscle atrophy in contrast to activation of FoxO that also induces skeletal muscle wasting, underscores an important but poorly understood paradox in that genetic manipulations that result in either enhanced macroautophagy or inhibition of macroautophagy both result in similar skeletal muscle atrophy and wasting phenotypes.
MACROAUTOPHAGY REGULATION
Macroautophagy (hereafter autophagy) is a cell-survival mechanism which degrades sequestered organelles and long-lived proteins through the lysosome [6 && ]. In normal muscle, low-protein diets upregulate autophagy that leads to the loss of muscle mass at least partially through lysosomal degradation [27] . Intriguingly, under other circumstances decreased autophagy can also lead to muscle atrophy. For example, the Col6a1-deficient mice display reduced autophagy flux and muscle wasting and in this animal model reactivation of autophagy is protective against muscle mass loss [28] .
The integrative regulation of autophagy initiation, cargo selection, trafficking, and lysosome fusion is a very complex process and the readers are referred to several reviews on this subject [6 && ,29]. Skeletal muscle deletion of an autophagy-essential gene, Atg7, resulted in muscle atrophy concomitant with increased expression of atrogins [30] . Since autophagy is considered a major cellular degradative system, one would have predicted that the genetic inhibition of autophagy would result in muscle hypertrophy and not the counter-intuitive atrophy/wasting phenotype observed, again highlighting the requirement of autophagy function in normal muscle homeostasis. Although the fibertype specificity was not examined in the ATG7 muscle knockout mice, analysis of muscle specific ATG5 knockout mice also demonstrates reduced autophagy selectively displaying an atrophy phenotype primarily in fast-twitch glycolytic fibers [31] .
Pompe's disease is a glycogen storage disease caused by defects in lysosomal GAA (acid a-glycosidase). GAA breaks down glucose polymers (glycogen) and when defective gluco-oligosaccharides accumulate in the lysosome resulting in lysosome swelling and neutralization of the lysosome pH, which is normally acidic [32 fiber types. Deletion of the Atg5 gene in GAA knockout mice results in an additive defect in autophagy, which gives rise to more severe muscle wasting than either the GAA or ATG5 single knockout mice. This greater autophagy inhibition resulted in massive autophagy vacuole build-up, accumulation of ubiquitinated protein in fast-twitch fibers, but no obvious effect on slow-twitch fibers. The selective muscle wasting of type II fibers that occurs by autophagy inhibition has been observed in other mouse models such as the Fyn-overexpressing transgenic mice [16 & ].
TRANSFORMING GROWTH FACTOR BETA FAMILY
The signaling transduction of transforming growth factor beta (TGFb) superfamily is executed by components of ligands, receptors, and intracellular mediators and readers may refer to reviews for more details about that of TGFb 1 , myostatin, and activins [6 && , 34,35 & ]. Postnatal treatment of wild-type mice with TGFb 1 resulted in decreased cross-sectional area of extensor digitorum longus (EDL) type II fibers, that was correlated with increased atrogin1 expression suggesting a potential role for TGFb 1 signaling in muscle atrophy [36] . In this regard, Marfan's syndrome (MFS) is an autosomal-dominant systemic disease caused by mutation of FBN1 gene coding fibrillin-1, a connective tissue protein that normally binds TGFb 1 [37 & ]. Additionally, enhanced TGFb 1 signaling has been observed in dystophin-deficient mice and inhibition of TFGb signaling improves myopathies associated with congenital muscular dystrophy [38] .
In addition to TGFb 1 , myostatin (GDF-8) binds to the type IIB activin receptor (ActRIIB) and negatively regulates muscle mass [35 & ]. Myostatin is upregulated in cachexia of aging and in states of muscle paralysis [39 && ,40] . Both skeletal musclespecific and systematic overexpression of myostatin in mice display similar phenotypes of muscle atrophy with greater sensitivity of glycolytic type II fibers than oxidative type I fibers [39 && ]. In contrast, loss-of-function mutations in myostatin lead to increased muscle mass in several species. For example, embryonic and fetal muscle development in myostatin knockout mice (MSTN À/À ) is markedly increased with a 2-3-fold enhancement in muscle mass resulting from both hypertrophy and fiber hyperplasia, with a proportionally larger increase in glycolytic type II fast-twitch fibers [41] . Adult MSTN À/À mice display decreased type I fibers with increased type II fibers and a greater shift to type IIb fibers in EDL muscle [42] . The different sensitivity between fiber types may be partly related to the level of myostatin and its receptor, since myostatin has higher mRNA level in fast-twitch muscles [20] and EDL muscle has twice the amount of ActRIIB than that of the soleus muscle [43] . Myostatin/ActRIIB activates SMAD2/3 signaling and importantly Fiber-type specificity of skeletal muscle atrophy Wang and Pessin SMAD2/3 inhibition completely desensitizes ActRIIB-induced muscle atrophy [44] . Inhibition of myostatin by a dominant negative ActRIIB promotes muscle hypertrophy independent of muscle satellite cell recruitment consistent with a direct signaling effect on muscle catabolism [44] .
NUCLEAR FACTOR kB PATHWAY
The nuclear factor kB (NF-kB) regulation of muscle atrophy is predominantly executed by promoting proteasome-mediated degradation [45] . Activation of NF-kB has been detected in both physiological and pathological atrophic conditions such as denervation, unloading, aging, cancer, sepsis, diabetes, and which atrophy can be reversed by pharmacologic or genetic NF-kB inhibition [46 & ]. Close scrutiny of the NF-kB skeletal muscle literature suggests that fast fibers are predominantly affected. For example, overexpression of musclespecific IkB kinase b leads to severe decrease of muscle weight and fiber cross-sectional area in fast fiber-dominant muscles, but not soleus muscle [45] . This atrophy is largely due to enhanced proteasomemediated degradation through induction of MuRF1, and crossing with MuRF1 knockout (MuRF1 À/À ) mice 
Keywords
Models Results
Primarily affected fiber type References
Myostatin Mstn À/À mice, Fiber type transition from slow, oxidative fibers to fast, glycolytic fibers in both soleus and EDL muscles Fast fibers [41] Myostatin, ActRIIB Mstn À/À mice MSTN À/À mice have more gain of muscle mass and fiber number of EDL muscle than those of soleus muscle compared to WT mice.
Fast fibers [43] Follistatin, activin, myostatin
Fst À/þ mice Fst À/þ mice have higher percentage of type I fibers than WT mice Fast fibers [50] GAA Type II fibers [45] NF-kB Nfkb1 À/À mice In soleus muscle, hind limb unloading causes 17 and 33% cross-sectional reduction of slow and fast fibers, but only 15 and 10% corresponding reduction in Nfkb1 À/À mice. Moreover, in fast fiber dominant-plantaris muscle, Nfkb1 À/À mice completely abolished unloading-induced muscle atrophy.
Type II fibers [47] TWEAK/Fn14, MCK-TWEAK transgenic mice Compared to control, TWEAK transgenic mice show 36% reduction of cross sectional-area in fast fibers but only 7.2% reduction in slow fibers.
Type II fibers [48] TNFa, NF-kB, sarcopenia 6-month-old and 26-month-old Fischer 344 rats SVL muscle show greater muscle weight loss than soleus during aging, which is correlated with TNFa and NF-kB activity increase.
Type II fibers [49] can block this effect [45] . Disuse/immobilization leads to fatigue intolerance and a greater extent of atrophy in fast fibers than slow fibers, which process is accompanied with NF-kB activation [47] , and knocking out of NF-kB (NFkB À/À mice) inhibits muscle atrophy in fast fibers more robustly than in slow fibers [47] . The effect of NF-kB in muscle atrophy has also been examined by disrupting its upstream regulators. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) and its receptor Fn14 (fibroblast growth factor-inducible receptor 14) mediate NF-kB activity through TRAF6 (tumor necrosis factor a receptor adaptor protein 6) and negatively regulate skeletal muscle mass [46 & ]. Muscle specific overexpression of TWEAK (MCK-TWEAK transgenic mice) causes 36% reduction of fiber cross-sectional area in fast-twitch fibers but only 7.2% in slowtwitch fibers, indicating its fast fiber preference, and this is related to accelerated muscle-specific protein degradation through MuRF1 but not Atro-gin1 [48] . Similarly increased tumor necrosis factor a (TNFa) has been correlated with sarcopenia, which show a greater atrophy in superficial vastus lateralis (SVL, predominantly type IIa and type IIb fibers) muscles than soleus muscle, and TNFa-induced NF-kB activation has been detected in aged SVL but not in aged soleus muscle [49] . Interestingly, denervation and immobilization-induced slow-to-fast fiber transition is prevented in multiple mouse models of NF-kB inhibition [47, 48] . These data indicate that in addition to the role of NF-kB activation in fast-twitch fiber atrophy, NF-kB signaling may also function in the loss of slow-twitch fibers [9 & ].
CONCLUSION
In general, disuse-related skeletal muscle atrophy that typically occurs during denervation, immobilization is primarily oxidative fiber-related, whereas nutrient-related atrophy such as cancer/aging cachexia, sepsis, and diabetes are more directed to glycolytic fiber wasting. At the molecular level, fiberspecific atrophy appears to be attributed to different signaling pathways, and most of them are relevant to abnormality of protein degradation ( Fig. 1 and Table 2 ). PGC1a protects slow-twitch oxidative fibers from atrophy. On the contrary, FoxO family, TGFb family, autophagy inhibition, and NF-kB signaling tend to primarily affect fast-twitch glycolytic fibers, although the specificity of these signals are still under debate. Further study is necessary to molecularly distinguish the relative signaling events and mechanisms accounting for the skeletal muscle atrophy in general and specifically the events accounting for fiber type selectively. Understanding these detailed issues will provide important insight in developing therapeutic approaches that can be used to prevent skeletal muscle atrophy under specific degenerative conditions. 
